FdaApplication
BLA 761099
Identifiers
- fda_app_no: BLA761099
Properties
| Property | Value |
|---|---|
| applicant_name | Pfizer Inc. |
| application_type | BLA |
| approval_date | 2019-06-27 |
Revenue by product
ZIRABEV
| Period | Revenue |
|---|---|
| Q4 2023 | $89.0M |
| Q3 2023 | $100.0M |
| Q2 2023 | $106.0M |
| Q1 2023 | $129.0M |
| Q4 2022 | $130.0M |
| Q3 2022 | $146.0M |
| Q2 2022 | $138.0M |
| Q1 2022 | $147.0M |
| Q4 2021 | $133.0M |
| Q3 2021 | $96.0M |
| Q2 2021 | $129.0M |
| Q1 2021 | $86.0M |
| Q4 2020 | $80.0M |
| Q3 2020 | $48.0M |
| Q2 2020 | $9.0M |
| Q1 2020 | $6.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (2)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| ZIRABEV | BEVACIZUMAB-BVZR | 100MG/4ML (25MG/ML) | Injection |
| ZIRABEV | BEVACIZUMAB-BVZR | 400MG/16ML (25MG/ML) | Injection |
2 products